Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas

Cancer

Volumn 117, Issue 7, 2011, Pages 1377-1385

  Grozinsky Glasberg, Simona ^a,b   Barak, Dganit ^c   Fraenkel, Merav ^c   Walter, Martin A ^d   Müeller Brand, Jan ^d   Eckstein, Joseph ^a   Applebaum, Liat ^c   Shimon, Ilan ^a,b   Gross, David J ^c  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

DOTATOC; gastrin; gastrinoma; radioligand; somatostatin; tumor response

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTIDE LUTETIUM 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTIDE YTTRIUM 90; ANGIOPEPTIN; DEXAMETHASONE; GALLIUM 68; GASTRIN; INDIUM 111; LUTETIUM 177; OCTREOTIDE; ONDANSETRON; PENTETREOTIDE; PROTON PUMP INHIBITOR; RADIOLIGAND; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; GASTRIN BLOOD LEVEL; GASTRIN RELEASE; GASTRINOMA; HUMAN; INOPERABLE CANCER; ISOTOPE LABELING; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NAUSEA; NEUROENDOCRINE TUMOR; PEPTIC ULCER; PRIORITY JOURNAL; RADIODIAGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; SYMPTOM; TUMOR VOLUME;

EID: 79952853547     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25646     Document Type: Article

References (38)

1. Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006; 84: 173-182. (Pubitemid 46361051)
2. Rindi G, Kloppel G., Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology. 2004; 80 (suppl 1): 12-15. (Pubitemid 39382361)
3. Mignon M, Cadiot G., Natural history of gastrinoma: lessons from the past. Ital J Gastroenterol Hepatol. 1999; 31 (suppl 2): S98-S103. (Pubitemid 29527876)
4. Li ML, Norton JA., Gastrinoma. Curr Treat Options Oncol 2001; 2: 337-346.
5. Howard TJ, Zinner MJ, Stabile BE, Passaro E Jr., Gastrinoma excision for cure. A prospective analysis. Ann Surg. 1990; 211: 9-14. (Pubitemid 20027876)
6. Landor JH., Control of the Zollinger-Ellison syndrome by excision of primary and metastatic tumor. Am J Surg. 1984; 147: 406-409. (Pubitemid 14154597)
7. Stabile BE, Morrow DJ, Passaro E Jr., The gastrinoma triangle: operative implications. Am J Surg. 1984; 147: 25-31. (Pubitemid 14220378)
8. Ellison EC, Sparks J, Verducci JS, et al. 50-year appraisal of gastrinoma: recommendations for staging and treatment. J Am Coll Surg. 2006; 202: 897-905. (Pubitemid 43776448)
9. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol. 1999; 17: 615-630. (Pubitemid 29075250)
10. Pellicano R, De Angelis C, Resegotti A, Rizzetto M., Zollinger-Ellison syndrome in 2006: concepts from a clinical point of view. Panminerva Med. 2006; 48: 33-40. (Pubitemid 43875420)
11. DeLellis RA, Eng C, Heitz PU, Lloyd RV., World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon, France: IARC; 2009.
12. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655. (Pubitemid 13149996)
13. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J., The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001; 12: 941-945. (Pubitemid 32725766)
14. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001; 28: 1319-1325.
15. Iten F, Muller B, Schindler C, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007; 13: 6696-6702. (Pubitemid 350206806)
16. Iten F, Muller B, Schindler C, et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer. 2009; 115: 2052-2062.
17. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993; 20: 716-731. (Pubitemid 23284773)
18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
19. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449: 395-401. (Pubitemid 44451313)
20. Arnold R, Rinke A, Schmidt C, Hofbauer L., Endocrine tumours of the gastrointestinal tract: chemotherapy. Best Pract Res Clin Gastroenterol. 2005; 19: 649-656.
21. Carty SE, Jensen RT, Norton JA., Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery. 1992; 112: 1024-1031.
22. Plockinger U, Wiedenmann B., Endocrine tumours of the gastrointestinal tract. Management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005; 19: 553-576.
23. Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer. 2002; 94: 331-343. (Pubitemid 34081361)
24. Reubi JC, Macke HR, Krenning EP., Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med. 2005; 46 (suppl 1): 67S-75S. (Pubitemid 47619021)
25. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005; 23: 2754-2762. (Pubitemid 46179465)
26. de Jong M, Breeman WA, Bernard BF, et al. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med. 2001; 42: 1841-1846. (Pubitemid 34016355)
27. Forrer F, Waldherr C, Maecke HR, Mueller-Brand J., Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006; 26: 703-707. (Pubitemid 43206037)
28. Waldherr C, Haldemann A, Maecke HR, Crazzolara A, Mueller-Brand J., Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue. Clin Oncol (R Coll Radiol). 2000; 12: 121-123. (Pubitemid 30261246)
29. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002; 43: 610-616. (Pubitemid 34507110)
30. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005; 46 (suppl 1): 62S-66S. (Pubitemid 47619020)
31. Buccheri G, Ferrigno D, Tamburini M., Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996; 32A: 1135-1141.
32. de Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002; 32: 133-140. (Pubitemid 34311079)
33. Valkema R, de Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002; 32: 110-122. (Pubitemid 34311077)
34. van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ., Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010; 51: 383-390.
35. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE., Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002; 32: 123-132. (Pubitemid 34311078)
36. Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008; 35: 1847-1856.
37. Forrer F, Uusijarvi H, Storch D, Maecke HR, Mueller-Brand J., Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med. 2005; 46: 1310-1316. (Pubitemid 43733480)
38. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003; 30: 417-422. (Pubitemid 36692868)